Related Experiment Videos
[Urinary incontinence: new pharmacologic therapies]
J E Robles García1, J J Zudaire Bergera, D Rosell Costa
1Departamento de Urología, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra. jerobles@unav.es
Revista De Medicina De La Universidad De Navarra
|April 9, 2005
Summary
New medications show promise for bladder control issues. Duloxetine offers a safe and effective oral treatment for stress urinary incontinence (SUI), while Solifenacin is effective for overactive bladder syndrome (OAB).
Area of Science:
- Urology
- Pharmacology
Context:
- Overactive bladder syndrome (OAB) and stress urinary incontinence (SUI) significantly impact quality of life.
- Current treatments for SUI include surgery and behavioral therapies.
- Pharmacological interventions are being explored for both OAB and SUI.
Purpose:
- To review the efficacy and safety of emerging pharmacological treatments for OAB and SUI.
- To highlight Duloxetine as a potential oral treatment for SUI.
- To present Solifenacin as an effective muscarinic receptor antagonist for OAB.
Summary:
- Duloxetine, an oral medication, demonstrates clinical safety and effectiveness for treating stress urinary incontinence (SUI).
- Solifenacin, a novel muscarinic receptor antagonist, has proven clinically effective, safe, and well-tolerated in trials for overactive bladder syndrome (OAB).
Impact:
- These findings suggest new therapeutic options for patients suffering from OAB and SUI.
- Duloxetine may offer a non-surgical alternative for SUI management.
- Solifenacin provides a well-tolerated pharmacological approach for OAB treatment.